Day Two
Thursday, January 20, 2022
8:00 am Chair’s Opening Remarks
A Deep Dive into DNA Damage Repair for GBM
8:10 am Targeting DNA Repair in Glioblastoma: New Era of Brain Penetrant Agents
Synopsis
- Aberrant DNA repair in malignant gliomas
- Functional interplay between cancer cell metabolism and DNA repair
- Brain penetrant DNA repair inhibitor efficacy in malignant gliomas
8:40 am Inovio’s DNA Medicine for the Treatment of Glioblastoma
Synopsis
- Using novel DNA-encoded medicines to treat human cancers such as GBM
- Generating robust, specific anti-tumor T cells against GBM antigens
- Combining DNA medicine with immune checkpoint inhibitors to build
clinical responses
9:10 am Targeting the DNA Damage Response in Glioma: Emerging New Concepts and Novel Directions
Synopsis
- Overview of the DNA damage response (DDR) and how it can be targeted therapeutically for GBM
- Review on promising new DDR inhibitors and DNA damaging agents, which are either in development or in the clinic for GBM
- Discuss emerging DDR targets, key hurdles, and future directions in the GBM space
9:40 am Morning Break & Networking
Financing BioPharma for Rapid GBM Drug Development
10:40 am Panel: It’s All in the Money – Funding Challenges & Opportunities in the GBM Space
Synopsis
- Explore the challenges of funding development
- How can drug developers inspire and attract companies to invest in their novel preclinical glioblastoma development and pipeline?
- How can the industry come together to overcome the paucity of funding?
Optimizing Immunotherapies for GBM Drug Development
11:40 am Immunotherapy of Brain Cancer: Past, Present and Future
Synopsis
- Challenges of designing & evaluating clinical trials for immunotherapies in the GBM field
- Strategies to sensitize glioblastoma to immune therapies
- Exploring immune therapy resistance in glioblastoma
12:10 pm Mechanisms of Immunosuppression
Synopsis
- Understand current landscape of immunotherapy for brain tumors
- Understand the current obstacles for developing effective immunotherapies for brain tumors
12:40 pm Lunch & Networking
1:40 pm Leveraging the Lysosome to Treat Glioblastoma
Synopsis
- BXQ-350 – a unique, first in class, lysosomal protein (in lipid nanovesicle) involved in cellular homeostasis
- Phase 1 clinical trial findings of extraordinary safety and tolerability with monotherapy effect
- Planned clinical trials in newly diagnosed GBM – combination therapy
with radiation and temozolomide
2:10 pm Optimization of an Oncolytic HSV-1 for the Treatment of Glioblastoma
Synopsis
- Optimization of oHSV backbone 7 Transgenes
- Development of clinical candidate oncolytic virus
2:40 pm STINGing GBM
Synopsis
- Characterization of the unique immune biology of the glioblastoma microenvironment
- Background on the role of the STING activation pathway in glioblastoma
- Preclinical data of STING agonists and potential lead candidates for clinical trials
3:10 pm Targeting Clonal Heterogeneity In Treatment-Refractory GBM With Empiric Polytherapy
Synopsis
- Review the biological profile of treatment-refractory glioblastoma
- Explore the application of an integrative multi-omics target discovery platform for human GBM which incorporates DNA cellular barcoding, glycocapture profiling of the cell surface proteome, RNA sequencing, single-cell sequencing and genome-wide CRISPR screening of primary and recurrent GBM
- Review the rationale for combinatorial polytherapy for targeting intratumoral heterogeneity and therapy-driven clonal evolution found in GBM recurrence
3:10 pm Afternoon Break & Refreshments
4:10 pm Novel Hydrogel-Based Localized Treatment For Glioblastoma
Synopsis
- Discovery of a novel target for Glioblastoma using a machine learning algorithm
- Development of a tailored hydrogel-based drug delivery system to be used as adjunct to surgery
- Presentation of preclinical in vitro and in vivo data supporting clinical
translation
4:40 pm Targeting Circadian Clock Proteins in Glioblastoma
Synopsis
- Clock proteins exhibit aberrant functions in glioblastoma stem cells
- We are developing a series of small molecule tool compounds that target the activity of clock proteins
- Preclinical data will be presented assessing the potential for novel
therapeutics
5:10 pm Xenogeneic Corneal Epithelial Cells Derived Vesicles Containing P53 as a Novel GBM Therapy
Synopsis
- Utilization of extracellular vesicles as delivery vehicle in brain tumors
- Preclinical results accumulated by ExoProTher
5:40 pm End of Day Two
